Veracyte (NASDAQ: VCYT) reported Q1 EPS of ($0.34), $0.03 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $11.2 million versus the consensus estimate of $10.83 million.

2015 Financial Outlook

Veracyte reiterates its 2015 annual revenue guidance of $48 million to $53 million, as well as its forecast to achieve annual Afirma GEC test volume in the range of 19,000 to 21,000.

For earnings history and earnings-related data on Veracyte (VCYT) click here.